Pharmacogenetic Influence of GST Polymorphisms on Anthracycline-Based Chemotherapy Responses and Toxicity in Breast Cancer Patients: A Multi-Analytical Approach
Background and Objective Chemotherapeutic drug treatment outcomes are genetically determined. Polymorphisms in genes encoding phase II drug metabolizing enzyme glutathione-S-transferase (GST) can possibly predict treatment outcomes, and can be of prognostic significance in breast cancer patients. The aim of this study was to determine the role of genetic variations in GST in predicting response to, and toxicity of, anthracycline-based chemotherapy in breast cancer patients. Method Two hundred and seven patients treated with anthracycline-based chemotherapy were genotyped for GSTM1 and GSTT1 deletion polymorphisms, and GSTP1 Ile 105 Val (rs1695), by polymerase chain reaction (PCR)/
This work proposes a known-plaintext attack on the Shrinking Generator through its characterization by means of Cellular Automata. It is based on the computation of the characteristic polynomials of sub-automata and on the generation of the Galois field associated to one of the Linear Feedback Shift Registers components of the generator. The proposed algorithm allows predicting a large number of unseen bits of the keystream sequence, thanks to the knowledge of both registers lengths, the characteristic polynomial of one of the registers, and some keystream bits.